Crossword Solver > found answer > BIOSIMILAR

Welcome to Anagrammer Crossword Genius! Keep reading below to see if biosimilar is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on biosimilar.

CROSSWORD
ANSWER

biosimilar

Searching in Crosswords ...

The answer BIOSIMILAR has 0 possible clue(s) in existing crosswords.

Searching in Word Games ...

The word BIOSIMILAR is NOT valid in any word game. (Sorry, you cannot play BIOSIMILAR in Scrabble, Words With Friends etc)

There are 10 letters in BIOSIMILAR ( A¹B³I¹L¹M³O¹R¹S¹ )

To search all scrabble anagrams of BIOSIMILAR, to go: BIOSIMILAR

Rearrange the letters in BIOSIMILAR and see some winning combinations

5 letters out of BIOSIMILAR

4 letters out of BIOSIMILAR

3 letters out of BIOSIMILAR

ABO ABS AIL AIM AIR AIS ALB ALS AMI ARB ARM ARS BAL BAM BAR BAS BIO BIS BOA BOS BRA BRO ISM LAB LAM LAR LAS LIB LIS LOB MAR MAS MIB MIL MIR MIS MOA MOB MOL MOR MOS OAR OBA OBI OIL OMS ORA ORB ORS RAI RAM RAS RIA RIB RIM ROB ROM SAB SAL SIB SIM SIR SOB SOL SOM SRI

2 letters out of BIOSIMILAR

AB AI AL AM AR AS BA BI BO IS LA LI LO MA MI MO OI OM OR OS SI SO

Searching in Dictionaries ...

Definitions of biosimilar in various dictionaries:

BIOSIMILAR - A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an ori...

Word Research / Anagrams and more ...

Keep reading for additional results and analysis below.

Biosimilar description
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. * Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilars, must maintain consistent quality and clinical performance throughout their lifecycle. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, to the exact fermentation and purification process, or to the active drug substance, but they have access to the commercialized innovator product. Overall, it is harder to ascertain fungibility between generics and innovators among biologics than it is among totally synthesized and semisynthesized drugs. That is why the name "biosimilar" was coined to differentiate them from small-molecule generics. A simple analogy, often used to explain the difference, is to compare wine with soda pop. It is harder to say objectively that two bottles of wine from two wineries are "sufficiently interchangeable," because of differences in yeast strain, weather, and year of grape harvest, than it is to say that two bottles of soda pop of the same flavor coming from two bottling plants are "sufficiently interchangeable" because they contain the same flavoring powder. * Drug-related authorities such as the EU's European Medicines Agency (EMA), the US's Food and Drug Administration (FDA), and the Health Products and Food Branch of Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies demonstrate that the biological product is highly similar to the reference product, despite minor differences in clinically inactive components, animal studies (including the assessment of toxicity), and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and is intended to be used and for which licensure is sought for the biological product. * In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted to demonstrate their highly-similar properties. Therefore, EMA has granted a marketing authorisation for only a few biosimilars since 2006,...

Biosimilar description

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
* Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilars, must maintain consistent quality and clinical performance throughout their lifecycle. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, to the exact fermentation and purification process, or to the active drug substance, but they have access to the commercialized innovator product. Overall, it is harder to ascertain fungibility between generics and innovators among biologics than it is among totally synthesized and semisynthesized drugs. That is why the name "biosimilar" was coined to differentiate them from small-molecule generics. A simple analogy, often used to explain the difference, is to compare wine with soda pop. It is harder to say objectively that two bottles of wine from two wineries are "sufficiently interchangeable," because of differences in yeast strain, weather, and year of grape harvest, than it is to say that two bottles of soda pop of the same flavor coming from two bottling plants are "sufficiently interchangeable" because they contain the same flavoring powder.
* Drug-related authorities such as the EU's European Medicines Agency (EMA), the US's Food and Drug Administration (FDA), and the Health Products and Food Branch of Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies demonstrate that the biological product is highly similar to the reference product, despite minor differences in clinically inactive components, animal studies (including the assessment of toxicity), and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and is intended to be used and for which licensure is sought for the biological product.
* In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted to demonstrate their highly-similar properties. Therefore, EMA has granted a marketing authorisation for only a few biosimilars since 2006,...

Anagrammer Crossword Solver is a powerful crossword puzzle resource site. We maintain millions of regularly updated crossword solutions, clues and answers of almost every popular crossword puzzle and word game out there. We encourage you to bookmark our puzzle solver as well as the other word solvers throughout our site. Explore deeper into our site and you will find many educational tools, flash cards and plenty more resources that will make you a much better player. Biosimilar: A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical p...